

EDITORIAL

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)

William Stohl*

See related research by Dillon *et al.*, <http://arthritis-research.com/content/12/2/R48>

Abstract

BLyS and APRIL are closely related members of the TNF ligand superfamily. These cytokines individually may contribute importantly to the development and maintenance of systemic lupus erythematosus (SLE). Dillon and colleagues demonstrate that in contrast to most members of the TNF ligand superfamily, which form only homotrimers, BLyS and APRIL can complex as heterotrimers. These complexes have *in vitro* biological activity, and circulating levels of BLyS/APRIL heterotrimers are frequently elevated in SLE, but not rheumatoid arthritis, patients. Although the mechanism and regulation of heterotrimer formation, the interconversion (if any) between homotrimers and heterotrimers, and, indeed, the normal physiologic role for such heterotrimers remain unknown, their preferential overexpression in SLE, but not in rheumatoid arthritis, raises the possibility that such heterotrimers may be playing a contributory role in SLE.

BLyS (also commonly known as BAFF) and the closely related APRIL are members of the TNF ligand superfamily. These molecules have enjoyed considerable attention from a diverse audience, ranging from basic investigators studying B-cell biology to clinical rheumatologists eagerly anticipating (and praying for) new (better) medications for their patients with systemic lupus erythematosus (SLE).

In general, individual members of the TNF ligand superfamily are highly parochial. That is, they routinely exist in homotrimeric form and, thereby, exclude other TNF ligand superfamily members from their complex domains. In sharp contrast, the recent report by Dillon and colleagues reminds us that BLyS and APRIL can, and

do, couple with each other as heterotrimers [1]. By extending the previous findings of Roschke and colleagues [2], Dillon and colleagues have convincingly documented the *in vitro* biologic activity of their recombinant BLyS/APRIL heterotrimers (whose stoichiometry is predominantly two parts APRIL plus one part BLyS) and the ability of soluble fusion proteins expressing either of two BLyS receptors (TACI and BCMA, which each also bind APRIL), but not the third BLyS receptor (BAFFR, which does not bind APRIL), to neutralize the *in vitro* biologic activity of these recombinant heterotrimers.

The clinical interest in the BLyS axis (which includes BLyS, APRIL, and the three BLyS receptors) initially stemmed from experiments in mice. These experiments, on the one hand, demonstrated causality between BLyS overexpression and development of SLE and, on the other hand, documented the amelioration of clinical disease in SLE mice following either treatment with a BLyS antagonist or the genetic elimination of BLyS [3-6]. The relevance of these observations in mice to the human condition was buttressed by the findings of BLyS overexpression in human SLE and the correlation of disease activity with circulating BLyS levels in these patients [7,8].

The appeal of BLyS as a therapeutic target has prompted substantial time and effort (and money) in the development of BLyS antagonists. The two BLyS antagonists that are the furthest advanced in clinical development are belimumab, an anti-BLyS monoclonal antibody, and atacicept, a fusion protein between TACI and the Fc portion of IgG. Results from phase II and phase III trials have demonstrated modest, but statistically significant, efficacy for belimumab in SLE [9,10], and late-stage clinical trials with atacicept in SLE are either currently underway or will soon begin.

It must be stressed that although belimumab and atacicept each binds to and neutralizes BLyS, their respective biologic activities importantly differ. Belimumab has no APRIL-neutralizing capacity, whereas atacicept is fully capable of neutralizing APRIL. Although APRIL-overexpressing mice, in marked contradistinction to BLyS-overexpressing mice, develop only subtle immunological abnormalities with no serological or clinical

*Correspondence: stohl@usc.edu

Division of Rheumatology, Department of Medicine, University of Southern California, Keck School of Medicine, 2011 Zonal Avenue HMR 711, Los Angeles, CA 90033, USA

autoimmune features [11], APRIL does contribute to plasma cell survival [12]. Accordingly, APRIL may enhance the longevity of autoantibody-producing plasma cells in a SLE host, and its neutralization may therefore result in decreased production of autoantibodies. Due to the fact that atacicept (TACI-Ig), but not the BLYS-specific BAFFR-Ig, neutralized the *in vitro* biologic activity of the recombinant BLYS/APRIL heterotrimers of Dillon and colleagues [1], atacicept probably neutralizes BLYS/APRIL heterotrimers (and APRIL homotrimers) *in vivo*, whereas belimumab may have little-to-no neutralizing effect on BLYS/APRIL heterotrimers (and no effect against APRIL homotrimers).

Whether this probable differential neutralization of BLYS/APRIL heterotrimers has any therapeutic ramifications remains entirely speculative. In principle, the biologic activity of BLYS/APRIL heterotrimers *in vivo* may be greater than, less than, or equal to that of BLYS or APRIL homotrimers. Accordingly, the net effect of therapeutic neutralization of APRIL concomitant with neutralization of BLYS might be beneficial, harmful, or neutral in the context of the ongoing autoimmunity of SLE. Of note, the recombinant heterotrimers of Dillon and colleagues were considerably less potent in promoting *in vitro* human B-cell proliferation than were the corresponding BLYS or APRIL homotrimers, raising the possibility (but certainly not proving) that the *in vivo* biologic activity of BLYS/APRIL heterotrimers may be relatively insignificant in comparison with those of BLYS or APRIL homotrimers.

Dillon and colleagues have also documented elevated circulating levels of native BLYS/APRIL heterotrimers in patients with SLE (but not with rheumatoid arthritis), although the precise stoichiometry of these heterotrimers *in vivo* remains unknown. The relative impotence of the recombinant BLYS/APRIL heterotrimers coupled to the uncertainty surrounding the *in vivo* stoichiometry of BLYS/APRIL heterotrimers highlight our current state of ignorance regarding these heterotrimers. We remain in the dark with regard to the mechanism and the regulation of heterotrimer formation *in vivo*, the interconversion (if any) between homotrimers and heterotrimers, and the dysregulation (if any) of such heterotrimers in disease states, such as SLE. Nonetheless, the preferential overexpression of heterotrimers in SLE, but not in rheumatoid arthritis, raises the possibility that such heterotrimers may be playing a contributory role in SLE. Development of reagents that can specifically neutralize the BLYS (or APRIL) homotrimers but not the heterotrimers (or *vice versa*) will help resolve the BLYS/APRIL heterotrimeric enigma.

Abbreviations

APRIL, a proliferation-inducing ligand; BAFF, B-cell activation factor of the TNF family; BLYS, B-lymphocyte stimulator; SLE, systemic lupus erythematosus; TACI, transmembrane activator and CAML interactor; TNF, tumor necrosis factor.

Competing interests

WS has received the following support: Human Genome Sciences, clinical trials support; Genentech, clinical trials support; and Xencor, pre-clinical studies support.

Acknowledgements

The present work was supported in part by NIH grant R01 AR050193.

Published: 22 April 2010

References

1. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'era M, Gross JA: **B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.** *Arthritis Res Ther* 2010, **12**:R48.
2. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone T-S: **BLYS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases.** *J Immunol* 2002, **169**:4314-4321.
3. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL: **Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.** *J Exp Med* 1999, **190**:1697-1710.
4. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH: **TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.** *Nature* 2000, **404**:995-999.
5. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, Frank D, Rice J, Diamond B, Yu KOA, Porcelli S, Davidson A: **Similarities and differences between selective and nonselective BAFF blockade in murine SLE.** *J Clin Invest* 2006, **116**:724-734.
6. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, Bixler SA, Ambrose CM, Scott ML, Stohl W: **Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF.** *J Immunol* 2006, **177**:2671-2680.
7. Cheema GS, Roschke V, Hilbert DM, Stohl W: **Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.** *Arthritis Rheum* 2001, **44**:1313-1319.
8. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W: **Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.** *Arthritis Rheum* 2008, **58**:2453-2459.
9. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW: **A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.** *Arthritis Rheum* 2009, **61**:1168-1178.
10. Navarra S, Guzman R, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan JL, Nasonov E, Tanasescu C, Kim HY, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group: **Belimumab, a BLYS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study.** *Arthritis Rheum* 2009, **60**:3859.
11. Stein JV, López-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodríguez D, Gómez-Caro R, de Jong J, Martínez-A C, Medema JP, Hahne M: **APRIL modulates B and T cell immunity.** *J Clin Invest* 2002, **109**:1587-1598.
12. Belnoue E, Pihlgren M, McGaha TL, Toungne C, Rochat A-F, Bossen C, Schneider P, Huard B, Lambert P-H, Siegrist C-A: **APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.** *Blood* 2008, **111**:2755-2764.

doi:10.1186/ar2976

Cite this article as: Stohl W: **Systemic lupus erythematosus and its ABCs (APRIL/BLYS complexes).** *Arthritis Research & Therapy* 2010, **12**:111.